Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia

Overview

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors identify learn more about biomarkers related to cancer. It may also help doctors to find better ways to treat cancer. PURPOSE: This research studies samples from patients with T-cell acute lymphoblastic leukemia (T-ALL).

Full Title of Study: “Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: May 2016

Detailed Description

OBJECTIVES: – Determine the metabolic status and regulation of primary T-cell acute lymphoblastic leukemia (T-ALL) relative to control resting peripheral T cells. – Establish the effects of metabolic inhibition on metabolic stress pathways and apoptosis. – Determine how metabolic inhibition interacts with chemotherapy or targeted therapy drugs to kill T-ALL cells. OUTLINE: T-ALL samples cultured alone or with gamma secretase inhibitors (GSI) or PI3K inhibitors are analyzed for metabolic characteristics including glucose transporter 1 (Glut1) expression, mitochondrial mass, phospho-flow for 5' adenosine monophosphate-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), and mammalian target of rapamycin (mTOR) by flow cytometry. T-ALL samples and normal CD4+ T cells (control) are also exposed to ± 2-deoxyglucose or ± the glutaminolysis inhibitor media and analyzed for metabolic stress responses over time in particular, AMPK activation, autophagy (immunofluorescence for LC3-II processing), and BCL2-associated X protein (Bak) and Bax activation to indicate apoptosis. These cells (T-ALL and control) are then cultured with cyclophosphamide, dexamethasone, or the B-cell CLL/lymphoma 2 (Bcl-2) inhibitor, ABT-737, to determine cell death over time.

Interventions

  • Genetic: gene expression analysis
  • Other: cell culture procedure
  • Other: flow cytometry
  • Other: laboratory biomarker analysis
  • Other: metabolic assessment

Clinical Trial Outcome Measures

Primary Measures

  • Metabolic status of primary T-ALL
  • Effects of metabolic inhibition on metabolic stress pathways and apoptosis
  • Metabolic inhibition interaction with chemotherapy or targeted drugs

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Sample from patients diagnosed with T-ALL – Samples from independent healthy donors obtained through the Gulf Coast Regional Blood Center (controls) PATIENT CHARACTERISTICS: – Not specified PRIOR CONCURRENT THERAPY: – Not specified

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Children’s Oncology Group
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jeffrey C. Rathmell, PhD, Principal Investigator, Duke Cancer Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.